Molecules for mood, memory, & mind
Developing targeted therapies for central nervous system disorders
What we do
We develop targeted therapies for the treatment of neuropsychiatric and neurodegenerative conditions by modulating key pathways associated with neuronal health.
Driven by the desire to improve the lives of patients with central nervous system disorders, we use our living human brain cell platform to identify and develop better therapeutics.
Our mission
We identify and optimize candidate medicines by examining their effects on living human brain cells which have been derived from induced pluripotent stem cells.
We focus on pathways involving neuroplasticity, neurogenesis, and neuroinflammation. Our lead candidate 4MT2001, is a potent and selective GSK3β inhibitor, providing a potentially safer and more effective alternative to lithium for patients with bipolar disorder. Our pipeline also includes potential breakthrough treatments for agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. Learn more
